Key Highlights

Risk & Performance

Based on historical performance

High Risk

Score: 90/100

Failure Rate

60.0%

3 terminated/withdrawn out of 5 trials

Success Rate

40.0%

-46.5% vs industry average

Late-Stage Pipeline

20%

1 trials in Phase 3/4

Results Transparency

0 of 2 completed trials have results

Key Signals

Phase 1

4(80.0%)

Phase 3

1(20.0%)

5Total

Phase 1(4)

Phase 3(1)

Loading network data...

Showing 5 of 5 trials

A Study of JHL1101 Versus MabThera® in Subjects With Severe Rheumatoid Arthritis

Role: lead

A Study to Compare the Efficacy and Safety of JHL1101 Versus Rituximab in Patients With Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL)

Role: lead

A Study to Compare the Bioequivalence and Safety of JHL1101 and Rituximab in CD20 Positive B Cell Lymphoma Patients

Role: lead

A Study to Compare the Pharmacokinetics of JHL1149 and Bevacizumab (Avastin) in Healthy Male Volunteers

Role: lead

A Comparative Safety and Pharmacokinetic Study of JHL1922 and Pulmozyme® in Healthy Subjects

Role: lead

All 5 trials loaded